Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15

Abstract Background The aim of the research is to study the human leukocyte antigen (HLA) class II allele frequencies in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) associated with anti-neurofascin 155 (NF155) antibodies. Methods Thirteen anti-NF155+ and 35 anti-NF155 negative (...

Full description

Bibliographic Details
Main Authors: Laura Martinez-Martinez, Ma. Cinta Lleixà, Gemma Boera-Carnicero, Andrea Cortese, Jérôme Devaux, Ana Siles, Yusuf Rajabally, Alicia Martinez-Piñeiro, Alejandra Carvajal, Julio Pardo, Emilien Delmont, Shahram Attarian, Jordi Diaz-Manera, Ilaria Callegari, Enrico Marchioni, Diego Franciotta, Luana Benedetti, Guiseppe Lauria, Oscar de la Calle Martin, Cándido Juárez, Isabel Illa, Luis Querol
Format: Article
Language:English
Published: BMC 2017-11-01
Series:Journal of Neuroinflammation
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12974-017-0996-1
id doaj-772aa3cea12b497a9c1eb885d150ae64
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Laura Martinez-Martinez
Ma. Cinta Lleixà
Gemma Boera-Carnicero
Andrea Cortese
Jérôme Devaux
Ana Siles
Yusuf Rajabally
Alicia Martinez-Piñeiro
Alejandra Carvajal
Julio Pardo
Emilien Delmont
Shahram Attarian
Jordi Diaz-Manera
Ilaria Callegari
Enrico Marchioni
Diego Franciotta
Luana Benedetti
Guiseppe Lauria
Oscar de la Calle Martin
Cándido Juárez
Isabel Illa
Luis Querol
spellingShingle Laura Martinez-Martinez
Ma. Cinta Lleixà
Gemma Boera-Carnicero
Andrea Cortese
Jérôme Devaux
Ana Siles
Yusuf Rajabally
Alicia Martinez-Piñeiro
Alejandra Carvajal
Julio Pardo
Emilien Delmont
Shahram Attarian
Jordi Diaz-Manera
Ilaria Callegari
Enrico Marchioni
Diego Franciotta
Luana Benedetti
Guiseppe Lauria
Oscar de la Calle Martin
Cándido Juárez
Isabel Illa
Luis Querol
Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15
Journal of Neuroinflammation
CIDP
Antibodies
NF155
HLA DRB1*15
author_facet Laura Martinez-Martinez
Ma. Cinta Lleixà
Gemma Boera-Carnicero
Andrea Cortese
Jérôme Devaux
Ana Siles
Yusuf Rajabally
Alicia Martinez-Piñeiro
Alejandra Carvajal
Julio Pardo
Emilien Delmont
Shahram Attarian
Jordi Diaz-Manera
Ilaria Callegari
Enrico Marchioni
Diego Franciotta
Luana Benedetti
Guiseppe Lauria
Oscar de la Calle Martin
Cándido Juárez
Isabel Illa
Luis Querol
author_sort Laura Martinez-Martinez
title Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15
title_short Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15
title_full Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15
title_fullStr Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15
title_full_unstemmed Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15
title_sort anti-nf155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to hla-drb15
publisher BMC
series Journal of Neuroinflammation
issn 1742-2094
publishDate 2017-11-01
description Abstract Background The aim of the research is to study the human leukocyte antigen (HLA) class II allele frequencies in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) associated with anti-neurofascin 155 (NF155) antibodies. Methods Thirteen anti-NF155+ and 35 anti-NF155 negative (anti-NF155neg) CIDP patients were included in a case-control study. The frequencies of the DRB1 HLA allele were analyzed in all patients while DQ frequencies were only studied in patients sharing the DRB1*15 allele. In silico HLA-peptide binding and NF155 antigenicity, predictions were performed to analyze overlap between presented peptides and antigenic regions. Results DRB1*15 alleles (DRB1*15:01 and DRB1*15:02) were present in 10 out of 13 anti-NF155+ CIDP patients and in only 5 out of 35 anti-NF155neg CIDP patients (77 vs 14%; OR = 20, CI = 4.035 to 99.13). DRB1*15 alleles appeared also in significantly higher proportions in anti-NF155+ CIDP than in normal population (77 vs 17%; OR = 16.9, CI = 4.434 to 57.30). Seven anti-NF155+ CIDP patients (53%) and 5 anti-NF155neg CIDP patients had the DRB1*15:01 allele (OR = 7, p = 0.009), while 3 anti-NF155+ CIDP patients and none of the anti-NF155neg CIDP patients had the DRB1*15:02 allele (OR = 23.6, p = 0.016). In silico analysis of the NF155 peptides binding to DRB1*15 alleles showed significant overlap in the peptides presented by the 15:01 and 15:02 alleles, suggesting functional homology. Conclusions DRB1*15 alleles are the first strong risk factor associated to a CIDP subset, providing additional evidence that anti-NF155+ CIDP patients constitute a differentiated disease within the CIDP syndrome.
topic CIDP
Antibodies
NF155
HLA DRB1*15
url http://link.springer.com/article/10.1186/s12974-017-0996-1
work_keys_str_mv AT lauramartinezmartinez antinf155chronicinflammatorydemyelinatingpolyradiculoneuropathystronglyassociatestohladrb15
AT macintalleixa antinf155chronicinflammatorydemyelinatingpolyradiculoneuropathystronglyassociatestohladrb15
AT gemmaboeracarnicero antinf155chronicinflammatorydemyelinatingpolyradiculoneuropathystronglyassociatestohladrb15
AT andreacortese antinf155chronicinflammatorydemyelinatingpolyradiculoneuropathystronglyassociatestohladrb15
AT jeromedevaux antinf155chronicinflammatorydemyelinatingpolyradiculoneuropathystronglyassociatestohladrb15
AT anasiles antinf155chronicinflammatorydemyelinatingpolyradiculoneuropathystronglyassociatestohladrb15
AT yusufrajabally antinf155chronicinflammatorydemyelinatingpolyradiculoneuropathystronglyassociatestohladrb15
AT aliciamartinezpineiro antinf155chronicinflammatorydemyelinatingpolyradiculoneuropathystronglyassociatestohladrb15
AT alejandracarvajal antinf155chronicinflammatorydemyelinatingpolyradiculoneuropathystronglyassociatestohladrb15
AT juliopardo antinf155chronicinflammatorydemyelinatingpolyradiculoneuropathystronglyassociatestohladrb15
AT emiliendelmont antinf155chronicinflammatorydemyelinatingpolyradiculoneuropathystronglyassociatestohladrb15
AT shahramattarian antinf155chronicinflammatorydemyelinatingpolyradiculoneuropathystronglyassociatestohladrb15
AT jordidiazmanera antinf155chronicinflammatorydemyelinatingpolyradiculoneuropathystronglyassociatestohladrb15
AT ilariacallegari antinf155chronicinflammatorydemyelinatingpolyradiculoneuropathystronglyassociatestohladrb15
AT enricomarchioni antinf155chronicinflammatorydemyelinatingpolyradiculoneuropathystronglyassociatestohladrb15
AT diegofranciotta antinf155chronicinflammatorydemyelinatingpolyradiculoneuropathystronglyassociatestohladrb15
AT luanabenedetti antinf155chronicinflammatorydemyelinatingpolyradiculoneuropathystronglyassociatestohladrb15
AT guiseppelauria antinf155chronicinflammatorydemyelinatingpolyradiculoneuropathystronglyassociatestohladrb15
AT oscardelacallemartin antinf155chronicinflammatorydemyelinatingpolyradiculoneuropathystronglyassociatestohladrb15
AT candidojuarez antinf155chronicinflammatorydemyelinatingpolyradiculoneuropathystronglyassociatestohladrb15
AT isabelilla antinf155chronicinflammatorydemyelinatingpolyradiculoneuropathystronglyassociatestohladrb15
AT luisquerol antinf155chronicinflammatorydemyelinatingpolyradiculoneuropathystronglyassociatestohladrb15
_version_ 1725833172445298688
spelling doaj-772aa3cea12b497a9c1eb885d150ae642020-11-24T22:03:06ZengBMCJournal of Neuroinflammation1742-20942017-11-011411610.1186/s12974-017-0996-1Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15Laura Martinez-Martinez0Ma. Cinta Lleixà1Gemma Boera-Carnicero2Andrea Cortese3Jérôme Devaux4Ana Siles5Yusuf Rajabally6Alicia Martinez-Piñeiro7Alejandra Carvajal8Julio Pardo9Emilien Delmont10Shahram Attarian11Jordi Diaz-Manera12Ilaria Callegari13Enrico Marchioni14Diego Franciotta15Luana Benedetti16Guiseppe Lauria17Oscar de la Calle Martin18Cándido Juárez19Isabel Illa20Luis Querol21Immunology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de BarcelonaNeuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de BarcelonaImmunology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de BarcelonaIRCCS Foundation C. Mondino National Neurological InstituteCentre de Recherche en Neurobiologie et Neurophysiologie de Marseille - CRN2M, UMR 7286, CNRS, Aix-Marseille UniversitéNeuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de BarcelonaRegional Neuromuscular Clinic, Queen Elizabeth Hospital, University Hospitals of BirminghamNeurology Department, Hospital Germans Trias i Pujol, Universitat Autònoma de BarcelonaDepartment of Neurology, Hospital Virgen de las NievesDepartment of Neurology, Hospital Clínico de SantiagoCentre de Recherche en Neurobiologie et Neurophysiologie de Marseille - CRN2M, UMR 7286, CNRS, Aix-Marseille UniversitéReferral Center for ALS and Neuromuscular Diseases, Timone University Hospital, Aix-Marseille UniversityNeuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de BarcelonaIRCCS Foundation C. Mondino National Neurological InstituteIRCCS Foundation C. Mondino National Neurological InstituteIRCCS Foundation C. Mondino National Neurological InstituteDepartment of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova and IRCCS AOU San Martino-ISTNeuroalgology Unit, IRCCS Foundation “Carlo Besta” Neurological InstituteImmunology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de BarcelonaImmunology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de BarcelonaNeuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de BarcelonaNeuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de BarcelonaAbstract Background The aim of the research is to study the human leukocyte antigen (HLA) class II allele frequencies in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) associated with anti-neurofascin 155 (NF155) antibodies. Methods Thirteen anti-NF155+ and 35 anti-NF155 negative (anti-NF155neg) CIDP patients were included in a case-control study. The frequencies of the DRB1 HLA allele were analyzed in all patients while DQ frequencies were only studied in patients sharing the DRB1*15 allele. In silico HLA-peptide binding and NF155 antigenicity, predictions were performed to analyze overlap between presented peptides and antigenic regions. Results DRB1*15 alleles (DRB1*15:01 and DRB1*15:02) were present in 10 out of 13 anti-NF155+ CIDP patients and in only 5 out of 35 anti-NF155neg CIDP patients (77 vs 14%; OR = 20, CI = 4.035 to 99.13). DRB1*15 alleles appeared also in significantly higher proportions in anti-NF155+ CIDP than in normal population (77 vs 17%; OR = 16.9, CI = 4.434 to 57.30). Seven anti-NF155+ CIDP patients (53%) and 5 anti-NF155neg CIDP patients had the DRB1*15:01 allele (OR = 7, p = 0.009), while 3 anti-NF155+ CIDP patients and none of the anti-NF155neg CIDP patients had the DRB1*15:02 allele (OR = 23.6, p = 0.016). In silico analysis of the NF155 peptides binding to DRB1*15 alleles showed significant overlap in the peptides presented by the 15:01 and 15:02 alleles, suggesting functional homology. Conclusions DRB1*15 alleles are the first strong risk factor associated to a CIDP subset, providing additional evidence that anti-NF155+ CIDP patients constitute a differentiated disease within the CIDP syndrome.http://link.springer.com/article/10.1186/s12974-017-0996-1CIDPAntibodiesNF155HLA DRB1*15